Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA. (ALTHBV)

  • End date
    Dec 31, 2022
  • participants needed
  • sponsor
    Third Affiliated Hospital, Sun Yat-Sen University
Updated on 24 February 2022


This study is to investigate the clinical efficacy and safety of Nucleoside (acid) analogues treatment in patients with normal Alanine Aminotransferase and positive Hepatitis B virus DNA.


Hepatitis b virus infection has always been a global public health problem that endangers national health. Current clinical guidelines do not recommend antiviral therapy for people with positive hepatitis b-DNA and normal Alanine Aminotransferase, but studies have found that viral replication is associated with an increased risk of cirrhosis and liver tumors. Nucleoside (acid) analogues can effectively inhibit viral reverse transcriptase, reduce HBV viral load in the blood, thereby reducing secondary inflammation, and contribute to liver cell regeneration and disease recovery. And its side effect is small, adverse reaction rate is low, use safety.

Condition Hepatitis B Virus
Treatment Tenofovir alafenamide Fumarate
Clinical Study IdentifierNCT04231565
SponsorThird Affiliated Hospital, Sun Yat-Sen University
Last Modified on24 February 2022


Yes No Not Sure

Inclusion Criteria

Positive hepatitis b surface antigen and hepatitis b antibody > 0.5 year
Age from 18 to 65 years old
Serum Alanine Aminotransferase(ALT) 1ULN at least 12 weeks
Positive Hepatitis b virus(HBV)
Do not receive nucleotide/nucleoside analogues or interferon treatment in the past half year

Exclusion Criteria

Other active liver diseases
Hepatocellular carcinoma or other malignancy
Pregnancy or lactation
Human immunodeficiency virus infection or congenital immune deficiency diseases; 5.Severe diabetes, autoimmune diseases; 6.Other important organ dysfunctions; 7.Using glucocorticoid; 8.Patients can not follow-up; 9.Investigator considering inappropriate
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note